U.S. markets closed

Precigen, Inc. (PGEN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.8300+0.0100 (+0.55%)
At close: 04:00PM EST
1.8500 +0.02 (+1.09%)
After hours: 07:58PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close1.8200
Bid1.8100 x 3000
Ask1.8500 x 2200
Day's Range1.7600 - 1.8800
52 Week Range1.1200 - 2.9000
Avg. Volume1,415,335
Market Cap459.343M
Beta (5Y Monthly)1.88
PE Ratio (TTM)N/A
EPS (TTM)-0.4720
Earnings DateFeb 27, 2023 - Mar 03, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.28
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for PGEN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Precigen, Inc.
    Analyst Report: Gilead Sciences, Inc.Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
    Fair Value
    Economic Moat
View more
  • American City Business Journals

    Germantown's Precigen raises $75M to advance treatments for rare diseases

    The clinical-stage company is developing gene and cell therapies for cancers, autoimmune disorders and infectious diseases.

  • PR Newswire

    Precigen Announces Closing of Public Offering of Common Stock

    Precigen, Inc. (Nasdaq: PGEN) announced today the closing of its previously announced underwritten public offering of common stock. Precigen sold 42,857,143 shares of its common stock at a public offering price of $1.75 per share. Gross proceeds to Precigen from the offering were approximately $75.0 million before deducting the underwriting discount and other offering expenses payable by Precigen.

  • PR Newswire

    Precigen Announces Pricing of $75.0 Million Public Offering of Common Stock

    Precigen, Inc. (Nasdaq: PGEN) today announced the pricing of an underwritten public offering of 42,857,143 shares of its common stock at a public offering price of $1.75 per share. Precigen has also granted the underwriters a 30-day option to purchase up to an additional 6,428,571 shares of its common stock. Gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $75.0 million, excluding any exerc